
Results
18
18 companies
Axsome Therapeutics
Market Cap: US$12.9b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$250.50
7D
-1.1%
1Y
146.4%
Ionis Pharmaceuticals
Market Cap: US$12.6b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$76.52
7D
3.0%
1Y
91.3%
Elanco Animal Health
Market Cap: US$11.6b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$23.96
7D
2.4%
1Y
74.1%
Waters
Market Cap: US$35.1b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$369.18
7D
3.4%
1Y
5.5%
ICON
Market Cap: US$10.9b
A clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally.
ICLR
US$158.08
7D
10.3%
1Y
8.3%
Natera
Market Cap: US$33.6b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$263.12
7D
16.2%
1Y
60.3%
Insmed
Market Cap: US$22.1b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$103.48
7D
5.1%
1Y
-1.3%
BioMarin Pharmaceutical
Market Cap: US$10.9b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$57.33
7D
4.2%
1Y
5.9%
Madrigal Pharmaceuticals
Market Cap: US$11.8b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$509.86
7D
2.0%
1Y
83.6%
Alnylam Pharmaceuticals
Market Cap: US$38.5b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$294.06
7D
4.0%
1Y
-8.7%
Viatris
Market Cap: US$18.3b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$15.93
7D
1.2%
1Y
79.1%
Jazz Pharmaceuticals
Market Cap: US$14.4b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$229.85
7D
1.3%
1Y
114.6%
BeOne Medicines
Market Cap: US$30.7b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$277.12
7D
5.5%
1Y
3.7%
Neurocrine Biosciences
Market Cap: US$16.2b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$166.09
7D
4.5%
1Y
30.0%
Royalty Pharma
Market Cap: US$31.9b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$54.28
7D
1.1%
1Y
51.2%
Merck
Market Cap: US$295.4b
Operates as a healthcare company worldwide.
MRK
US$120.60
7D
4.5%
1Y
51.4%
Krystal Biotech
Market Cap: US$10.0b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$347.90
7D
1.8%
1Y
144.1%
Gilead Sciences
Market Cap: US$155.3b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$125.15
7D
-0.2%
1Y
18.1%